Medcan Launches Galleri Multi-Cancer Early Detection Test in Canada

Strategic Insights -

Medcan, a global leader in proactive health and wellness, has announced the Canadian launch of the Galleri multi-cancer early detection test. This clinically validated test can detect more than 50 types of cancer before symptoms appear, including pancreatic, esophageal, ovarian, and liver cancer, which have no existing or routine screening options in Canada. The Galleri test uses a single blood draw and screens for a unique "fingerprint" of cancer, providing clients with personalized guidance from Medcan's clinical team.

Key Takeaways:

  • The Galleri test can detect more than 50 types of cancer before symptoms appear, including pancreatic, esophageal, ovarian, and liver cancer.
  • The test uses a single blood draw and screens for a unique "fingerprint" of cancer.
  • Clients receive results in approximately four weeks, along with personalized guidance from Medcan's clinical team.
  • The Galleri test has been clinically validated through a study involving over 385,000 participants.
  • Medcan is offering the Galleri test exclusively at its clinics in Toronto and Oakville.
  • The test is not a replacement for regular cancer screening tests, but rather a supplement to add to the client's existing health plan.

Statistics:

  • The Galleri test has a clinical program involving over 385,000 participants.
  • The test can detect more than 50 types of cancer before symptoms appear.
  • Clients receive results in approximately four weeks.
  • The Galleri test has been clinically validated through a study involving participants over the age of 50.
  • Medcan's clinics in Toronto and Oakville are offering the Galleri test exclusively.

Sources:

  • Medcan
  • Schrag D, et al. (2023). Blood-based tests for multi-cancer early detection (PATHFINDER): a prospective cohort study. Lancet, 402(10524), 1251-1260. doi: 10.1016/S0140-6736(23)01700-2
  • Klein EA, et al. (2021). Clinical validation of a targeted methylation-based multi-cancer early detection test using an independent validation set. Ann Oncol, 32(9), 1167-1177. doi: 10.1016/j.annonc.2021.05.806
  • Liu MC, et al. (2020). Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA. Ann Oncol, 31(6), 745-759. doi: 10.1016/j.annonc.2020.02.011
  • Thierry AR, et al. (2016). Origins, structures, and functions of circulating DNA in oncology. Cancer Metastasis Rev, 35, 347-376. doi: 10.1007/s10555-016-9629-x